Barry S. Oemar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barry S. Oemar has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Annick Werner
The Division of Cardiology and Cardiovascular Research Laboratory (B.S.O., A.W., T.F.L.), Department of Cardiovascular Surgery (D.-D.D.), Department of Neurosurgery (N.G.), University Hospital Bern, Bern, Switzerland; Laboratoire de Ge´ne´tique Mole´culaire des Eucaryotes du CNRS (J.-M.G.), Unite´ 184, INSERM, Strasbourg, France; Department of Medicine (M.N., W.M.), Division of Clinical Chemistry, University Hospital Freiburg, Germany; F. Hoffmann La Roche Ltd (J.R., M.P.), Basel, Switzerland
1 shared publicationDai-Do Do
The Division of Cardiology and Cardiovascular Research Laboratory (B.S.O., A.W., T.F.L.), Department of Cardiovascular Surgery (D.-D.D.), Department of Neurosurgery (N.G.), University Hospital Bern, Bern, Switzerland; Laboratoire de Ge´ne´tique Mole´culaire des Eucaryotes du CNRS (J.-M.G.), Unite´ 184, INSERM, Strasbourg, France; Department of Medicine (M.N., W.M.), Division of Clinical Chemistry, University Hospital Freiburg, Germany; F. Hoffmann La Roche Ltd (J.R., M.P.), Basel, Switzerland
1 shared publicationJean-Marie Garnier
The Division of Cardiology and Cardiovascular Research Laboratory (B.S.O., A.W., T.F.L.), Department of Cardiovascular Surgery (D.-D.D.), Department of Neurosurgery (N.G.), University Hospital Bern, Bern, Switzerland; Laboratoire de Ge´ne´tique Mole´culaire des Eucaryotes du CNRS (J.-M.G.), Unite´ 184, INSERM, Strasbourg, France; Department of Medicine (M.N., W.M.), Division of Clinical Chemistry, University Hospital Freiburg, Germany; F. Hoffmann La Roche Ltd (J.R., M.P.), Basel, Switzerland
1 shared publicationJoachim Rupp
The Division of Cardiology and Cardiovascular Research Laboratory (B.S.O., A.W., T.F.L.), Department of Cardiovascular Surgery (D.-D.D.), Department of Neurosurgery (N.G.), University Hospital Bern, Bern, Switzerland; Laboratoire de Ge´ne´tique Mole´culaire des Eucaryotes du CNRS (J.-M.G.), Unite´ 184, INSERM, Strasbourg, France; Department of Medicine (M.N., W.M.), Division of Clinical Chemistry, University Hospital Freiburg, Germany; F. Hoffmann La Roche Ltd (J.R., M.P.), Basel, Switzerland
1 shared publicationMarkus Nauck
The Division of Cardiology and Cardiovascular Research Laboratory (B.S.O., A.W., T.F.L.), Department of Cardiovascular Surgery (D.-D.D.), Department of Neurosurgery (N.G.), University Hospital Bern, Bern, Switzerland; Laboratoire de Ge´ne´tique Mole´culaire des Eucaryotes du CNRS (J.-M.G.), Unite´ 184, INSERM, Strasbourg, France; Department of Medicine (M.N., W.M.), Division of Clinical Chemistry, University Hospital Freiburg, Germany; F. Hoffmann La Roche Ltd (J.R., M.P.), Basel, Switzerland
1 shared publicationMichael Pech
The Division of Cardiology and Cardiovascular Research Laboratory (B.S.O., A.W., T.F.L.), Department of Cardiovascular Surgery (D.-D.D.), Department of Neurosurgery (N.G.), University Hospital Bern, Bern, Switzerland; Laboratoire de Ge´ne´tique Mole´culaire des Eucaryotes du CNRS (J.-M.G.), Unite´ 184, INSERM, Strasbourg, France; Department of Medicine (M.N., W.M.), Division of Clinical Chemistry, University Hospital Freiburg, Germany; F. Hoffmann La Roche Ltd (J.R., M.P.), Basel, Switzerland
1 shared publication
Latest Publications
- 1 August 1997
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (8) , 1483-1489
Connective Tissue Growth Factor
Connective tissue growth factor (CTGF) is a novel cysteine-rich, secreted peptide, which is implicated in human atherosclerosis and fibrotic disorders such as systemic scleroderma. CTGF is a member of the peptide family that includes serum-induced immediate early gene products, a v- src –induced peptide, and a putative proto-oncogene. The CTGF gene family is a modular protein and is conserved throughout evolution. CTGF mRNA has been found in the human, mouse, chicken, frog, and fly. The functions of the CTGF gene family include embryogenesis, wound healing, and regulation of extracellular matrix production. Human CTGF is undetectable in normal blood vessels but overexpressed in atherosclerotic lesions, suggesting an important role in atherogenesis.
- 1 August 1997
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (8) , 1483-1489
Connective Tissue Growth Factor
Connective tissue growth factor (CTGF) is a novel cysteine-rich, secreted peptide, which is implicated in human atherosclerosis and fibrotic disorders such as systemic scleroderma. CTGF is a member of the peptide family that includes serum-induced immediate early gene products, a v- src –induced peptide, and a putative proto-oncogene. The CTGF gene family is a modular protein and is conserved throughout evolution. CTGF mRNA has been found in the human, mouse, chicken, frog, and fly. The functions of the CTGF gene family include embryogenesis, wound healing, and regulation of extracellular matrix production. Human CTGF is undetectable in normal blood vessels but overexpressed in atherosclerotic lesions, suggesting an important role in atherogenesis.
- 18 February 1997
- Published by Wolters Kluwer Health in Circulation
- Vol. 95 (4) , 831-839
Human Connective Tissue Growth Factor Is Expressed in Advanced Atherosclerotic Lesions
Background Atherosclerosis affects certain but not all vascular beds of the human circulation. Its molecular mechanisms are only partially understood. Human connective tissue growth factor (hCTGF) is a novel cysteine-rich, secreted polypeptide. hCTGF is implicated in connective tissue formation, which may play an important role in atherosclerosis. Methods and Results By using a differential cloning technique, we isolated a cDNA clone from a human aorta cDNA library, which is identical to hCTGF. Northern analysis shows that hCTGF mRNA was expressed at 50- to 100-fold higher levels in atherosclerotic blood vessels compared with normal arteries. In vascular smooth muscle cells, high-level expression of hCTGF mRNA was induced by transforming growth factor-β1. Using in situ hybridization and immunohistochemistry, we found that all advanced atherosclerotic lesions of human carotid arteries (eight patients; mean age, 69; age range, 57 to 85 years) and femoral arteries (two patients; mean age, 71.5 years) that we tested expressed high levels of both hCTGF mRNA and protein. hCTGF expression was localized mainly to smooth muscle cells in the plaque lesions that are negative for proliferating cell nuclear antigen staining. In addition, some CD-31–positive endothelial cells of plaque vessels expressed high levels of hCTGF mRNA and protein. hCTGF-positive cells were found predominantly in areas with extracellular matrix accumulation and fibrosis. In contrast, in normal arteries, we were unable to detect either hCTGF mRNA or immunoreactive hCTGF protein. Conclusions In the present study, we have shown for the first time that both hCTGF mRNA and protein are expressed in human arteries in vivo and that hCTGF may represent a novel factor expressed at high levels specifically in advanced lesions and may play a role in the development and progression of atherosclerosis.
- 18 February 1997
- Published by Wolters Kluwer Health in Circulation
- Vol. 95 (4) , 831-839
Human Connective Tissue Growth Factor Is Expressed in Advanced Atherosclerotic Lesions
Background Atherosclerosis affects certain but not all vascular beds of the human circulation. Its molecular mechanisms are only partially understood. Human connective tissue growth factor (hCTGF) is a novel cysteine-rich, secreted polypeptide. hCTGF is implicated in connective tissue formation, which may play an important role in atherosclerosis. Methods and Results By using a differential cloning technique, we isolated a cDNA clone from a human aorta cDNA library, which is identical to hCTGF. Northern analysis shows that hCTGF mRNA was expressed at 50- to 100-fold higher levels in atherosclerotic blood vessels compared with normal arteries. In vascular smooth muscle cells, high-level expression of hCTGF mRNA was induced by transforming growth factor-β1. Using in situ hybridization and immunohistochemistry, we found that all advanced atherosclerotic lesions of human carotid arteries (eight patients; mean age, 69; age range, 57 to 85 years) and femoral arteries (two patients; mean age, 71.5 years) that we tested expressed high levels of both hCTGF mRNA and protein. hCTGF expression was localized mainly to smooth muscle cells in the plaque lesions that are negative for proliferating cell nuclear antigen staining. In addition, some CD-31–positive endothelial cells of plaque vessels expressed high levels of hCTGF mRNA and protein. hCTGF-positive cells were found predominantly in areas with extracellular matrix accumulation and fibrosis. In contrast, in normal arteries, we were unable to detect either hCTGF mRNA or immunoreactive hCTGF protein. Conclusions In the present study, we have shown for the first time that both hCTGF mRNA and protein are expressed in human arteries in vivo and that hCTGF may represent a novel factor expressed at high levels specifically in advanced lesions and may play a role in the development and progression of atherosclerosis.